Commonweath Laboratories and Cedars-Sinai Medical Center Enter into Exclusive License Agreement for Patents Used in the Diagnosis of Irritable Bowel Syndrome and Other Disorders Caused by Small Intestinal Bacterial Overgrowth
10/4/2013 9:20:52 AM
SALEM, Mass.--(BUSINESS WIRE)--Commonwealth Laboratories, Inc. and Cedars-Sinai Medical Center announce the signing of an exclusive license agreement for three patents owned by Cedars-Sinai that cover technology developed by Mark Pimentel, M.D., FRCPC, Director of Cedars-Sinai’s Gastrointestinal Motility Program and Laboratory, and Henry C. Lin, M.D. These patents describe the use of hydrogen and methane breath testing in the diagnosis of Irritable Bowel Syndrome and other disorders caused by Small Intestinal Bacterial Overgrowth. Small Intestinal Bacterial Overgrowth (SIBO) is a condition in which abnormally large amounts of bacteria—100,000 bacteria per ml of fluid or more—are present in the small intestine. Prominent gastroenterologists, including Dr. Pimentel, have identified SIBO as a leading cause of Irritable Bowel Syndrome (IBS).
Help employers find you! Check out all the jobs and post your resume.
comments powered by